-
1
المؤلفون: Egbert F. Smit, Buge Oz, Lukas Bubendorf, Stephen P. Finn, Lukas C. Heukamp, M. van den Heuvel, I. Marondel, A.O Grady, John R. Gosney, Anders Mellemgaard, Fabrice Duplaquet, Idris Bahce, Sayed M.S. Hashemi, Birgit Weynand, Xavier Durando, S.M.S. Samii, Patrick Pauwels, Pieter E. Postmus, Kim Monkhorst, Frédérique Penault-Llorca, S. Duin, Monika G. Looijen-Salamon, M.A. van der Drift, Ernst-Jan M. Speel, Wim Timens, Reinhard Buettner, N. Akyurek, Birgit I. Lissenberg-Witte, Erik Thunnissen, Birgit Guldhammer Skov, Ed Schuuring, Jens Benn Sørensen, Juergen Wolf, A.J. de Langen, Anne-Marie C. Dingemans
المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service de pneumologie, Pathology, Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pulmonary medicine
المصدر: Lung cancer: journal of the International Association for the Study of Lung Cancer
Lung Cancer, 138, pp. 13-18
Lung Cancer, 138, 13-18
Lung Cancer
Lung Cancer, 138, 13-18. ELSEVIER IRELAND LTD
Thunnissen, E, Lissenberg-Witte, B I, van den Heuvel, M M, Monkhorst, K, Skov, B G, Sørensen, J B, Mellemgaard, A, Dingemans, A M C, Speel, E J M, de Langen, A J, Hashemi, S M S, Bahce, I, van der Drift, M A, Looijen-Salamon, M G, Gosney, J, Postmus, P E, Samii, S M S, Duplaquet, F, Weynand, B, Durando, X, Penault-Llorca, F, Finn, S, Grady, A O, Oz, B, Akyurek, N, Buettner, R, Wolf, J, Bubendorf, L, Duin, S, Marondel, I, Heukamp, L C, Timens, W, Schuuring, E M D, Pauwels, P & Smit, E F 2019, ' ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib ', Lung Cancer, vol. 138, pp. 13-18 . https://doi.org/10.1016/j.lungcan.2019.09.023Test
Lung Cancer, 138, 13-18. Elsevier Ireland Ltd
Lung cancer, Vol. 138, p. 13-18 (2019)مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, INTERNATIONAL-ASSOCIATION, Stress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13], 0302 clinical medicine, alk, Non-small cell lung cancer, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Prospective Studies, In Situ Hybridization, Fluorescence, Gene Rearrangement, fluorescence in situ hybridisation, medicine.diagnostic_test, treatment, REARRANGEMENT, Middle Aged, OF-AMERICAN-PATHOLOGISTS, Prognosis, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], Immunohistochemistry, PREVALENCE, Survival Rate, LUNG-CANCER PATIENTS, Treatment Outcome, 030220 oncology & carcinogenesis, immunohistochemistry, Fish
, Female, Non small cell, medicine.drug, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 03 medical and health sciences, MOLECULAR TESTING GUIDELINE, All institutes and research themes of the Radboud University Medical Center, Crizotinib, Internal medicine, Biopsy, medicine, Humans, Protein Kinase Inhibitors, non-small cell lung cancer, business.industry, ADENOCARCINOMA, Treatment, 030104 developmental biology, COPY NUMBER, ALK, KINASE INHIBITORS GUIDELINE, Fluorescence in situ hybridisation, Human medicine, prognosis, business, Stage iv, Fluorescence in situ hybridization, IHC وصف الملف: pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fbd4c2857be1034f64d88d9f7a78b17Test
https://doi.org/10.1016/j.lungcan.2019.09.023Test -
2
المؤلفون: Michel M van den Heuvel, Johan Bussink, Paul N. Span, Monika G. Looijen-Salamon, Johannes H.A.M. Kaanders, Jasper Lok, Tineke W.H. Meijer, Bastiaan B J Tops
المصدر: Thoracic Cancer, Vol 10, Iss 12, Pp 2289-2299 (2019)
Thoracic Cancer, 10, 2289-2299
Thoracic Cancer, 10, 12, pp. 2289-2299
Thoracic Cancerمصطلحات موضوعية: non‐small cell lung cancer, 0301 basic medicine, Pulmonary and Respiratory Medicine, Lung Neoplasms, Glutamine, Cell, Fluorescent Antibody Technique, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], medicine.disease_cause, mutational status, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Genetic Association Studies, Neoplasm Staging, Messenger RNA, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], biology, business.industry, Glucose transporter, Original Articles, General Medicine, glycolysis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Glucose, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Mutation, biology.protein, Cancer research, Glutamine metabolism, Adenocarcinoma, Original Article, GLUT1, KRAS, business, Glucose Transporter Type 1, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405265537daea13a05ce68564bf55954Test
https://doi.org/10.1111/1759-7714.13226Test -
3
المؤلفون: Ernst-Jan M. Speel, Nils A. 't Hart, B. E. van den Borne, E. Van Der Heijden, Monika G. Looijen-Salamon, S. Riemersma, Lizza E.L. Hendriks, A. J. van der Wekken, Harry J.M. Groen, Ed Schuuring, Wim Timens, R. Pelgrim, A. Van Den Berg, Thijo J N Hiltermann, A.J. de Langen, N Werner, J. Staal-van den Brekel, Anne-Marie C. Dingemans, M. F. Mastik
المساهمون: Stem Cell Aging Leukemia and Lymphoma (SALL), Translational Immunology Groningen (TRIGR), Groningen Research Institute for Asthma and COPD (GRIAC), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Guided Treatment in Optimal Selected Cancer Patients (GUTS), CCA - Cancer Treatment and quality of life, Pulmonary medicine, Pulmonologie, Promovendi ODB, MUMC+: MA Med Staf Spec Longziekten (9), RS: GROW - R2 - Basic and Translational Cancer Biology, Pathologie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Epidemiologie
المصدر: Clinical Cancer Research, 23(15), 4251-4258. AMER ASSOC CANCER RESEARCH
Europe PubMed Central
Clinical Cancer Research, 23(15), 4251-4258. American Association for Cancer Research Inc.
Clinical Cancer Research, 23, 4251-4258
Clinical Cancer Research, 23, 15, pp. 4251-4258
Van Der Wekken, A J, Pelgrim, R, T Hart, N, Werner, N, Mastik, M F, Hendriks, L, Van Der Heijden, E H F M, Looijen-Salamon, M, De Langen, A J, Staal-Van Den Brekel, J, Riemersma, S, Van Den Borne, B E, Speel, E J M, Dingemans, A M C, Hiltermann, T J N, Van Den Berg, A, Timens, W, Schuuring, E & Groen, H J M 2017, ' Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non–small cell lung cancer ', Clinical Cancer Research, vol. 23, no. 15, pp. 4251-4258 . https://doi.org/10.1158/1078-0432.CCR-16-1631Testمصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Pathology, Pyridines, FUSION, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, GENE REARRANGEMENT, In Situ Hybridization, Fluorescence, CRIZOTINIB THERAPY, medicine.diagnostic_test, Middle Aged, Prognosis, Gene Expression Regulation, Neoplastic, CARCINOMAS, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.drug, Adult, medicine.medical_specialty, Biopsy, Fine-Needle, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Disease-Free Survival, 03 medical and health sciences, Crizotinib, Internal medicine, Biopsy, Biomarkers, Tumor, medicine, Carcinoma, Humans, IMMUNOHISTOCHEMISTRY, Lung cancer, Aged, IDENTIFICATION, business.industry, Receptor Protein-Tyrosine Kinases, Cancer, ADENOCARCINOMA, Gene rearrangement, IN-SITU HYBRIDIZATION, medicine.disease, COPY NUMBER, 030104 developmental biology, Pyrazoles, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::294301d2488887f96efb73185cf8e257Test
https://doi.org/10.1158/1078-0432.ccr-16-1631Test